|会社名||BioCryst Pharmaceuticals Inc （バイオクリスト・ファ―マシュ―ティカルズ）|
|分野（sector）||Health Care ヘルスケア|
|産業（industry）||Biotechnology: Biological Products (No Diagnostic Substances)|
|業種||バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care）|
|概要||事業概要 バイオクリスト・ファーマシューティカルズ（BioCryst Pharmaceuticals Inc.）はバイオテクノロジー企業である。病気の病因に関与する酵素をブロックする小分子薬の設計、最適化と開発を行う。同社は希少疾患の治療に集中する。同社はX線結晶学、分子構造のコンピュータモデリングと化学技術を利用して細胞生物学を制御する酵素の活性部位特性と三次元的な分子構造の解明に集中する。同社の薬剤候補はRAPIVAB、RAPIACTA、ALPIVAB、PERAMIFLU、Avoralstat、BCX7353、他の第二世代遺伝性血管浮腫（HAE）化合物、GalidesivirとForodesineなどを含む。同社の製品RAPIVABはペラミビルを含む。ALPIVABは静脈内ノイラミニダーゼ阻害剤である。Galidesivirは出血熱ウイルスの治療に向けの広域抗ウイルス（BSAV）研究プログラムである。Forodesineはがん治療薬としてMundipharmaによる開発されたプリンヌクレオシドホスホリラーゼ（PNP）阻害剤である。 バイオクリスト・ファ―マシュ―ティカルズは、米国のバイオ医薬品企業。疾患の発症を引き起こす酵素を阻害する薬剤の開発に従事。インフルエンザ患者の治療薬ペラミビル、痛風治療薬ウロデシン、血液学的悪性腫瘍の治療薬フォロデシン、遺伝性血管性浮腫（HAE）の治療薬BCX4161などの開発を行う。またエボラウィルスの治療用抗ウィルスの研究を手掛ける。 BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO™ (berotralstat) is approved in the United States and Japan for the prevention of HAE attacks in adults and pediatric patients 12 years and older, and under regulatory review for approval in the European Union and United Kingdom. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing.|
|本社所在地||4505 Emperor Blvd. Suite 200 Durham NC 27703 USA|
|代表者氏名||Robert A. Ingram ロバートA.イングラム|
|代表者役職名||Chairman of the Board 取締役会会長|
|市場名||NASDAQ National Market System|
|決算概要||決算概要 BRIEF: For the six months ended 30 June 2018 BioCryst Pharmaceuticals Inc. revenues increased 31% to $16.5M. Net loss increased 42% to $44.2M. Revenues reflect Collaborative and other research and dev increase from $5.7M to $12.7M. Higher net loss reflects General_Administrative increase from $5.9M to $17.1M (expense) Research and development increase of 21% to $39.5M (expense).|
7 Penny Stocks With Strong Insider Buying Signals 2023/03/05 17:10:56 InvestorPlace
When it comes to penny stocks , a diligent look at fundamentals and insider activity should be key to your research. After all, penny stocks with strong insider buying can potentially be strong opportunities. How so? If an insider, such as a C-suite executive or board member, is buying additional shares with their own capital, it’s a positive sign that they are bullish on the company’s future prospects. Fortunately for your average investor, insiders at publicly-traded companies are required to disclose their transactions in filings submitted to the US SEC. Plenty of online stock research tools enable you to filter for stocks where there has been a high level of insider buying. In fact, using these tools, I found seven penny stocks with strong insider buying. Let’s dive into each one, and see whether it is wise to follow their lead. ACER Acer Therapeutics $1.98 ADES Advanced Emissions $2.91 APLD Applied Digital $2.68 BLBX BioCryst $8.79 GLG TD Holdings $1.24 GLT Glatfelter $3.75 PRCH Porch Group $2.21 Acer Therapeutics (ACER) Source: John Brueske / Shutterstock Based in Newton, Massachusetts, Acer Therapeutics (NASDAQ: ACER ) is a clinical-stage biotech company focused on the development of treatments for rare and life-threatening diseases.
BioCryst Pharmaceuticals (BCRX) Presents At J.P. MORGAN HEALTHCARE CONFERENCE 2023/03/02 18:15:55 Seeking Alpha
The following slide deck was published by BioCryst Pharmaceuticals, Inc.
Have you been able to find a good deal on BioCryst Pharmaceuticals Inc.’s shares? 2023/03/02 13:40:00 US Post News
As of Wednesday, BioCryst Pharmaceuticals Inc.’s (NASDAQ:BCRX) stock closed at $8.83, down from $8.85 the previous day. While BioCryst Pharmaceuticals Inc. has underperformed by -0.23%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, BCRX fell by -46.84%, with highs and lows ranging from $18.60 to $7.61, […]
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Clear Channel Outdoor Holdings, Inc. (NYSE:CCO) – Overwhelming stocks 2023/03/01 12:52:27 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Clear Channel Outdoor Holdings, Inc. (NYSE:CCO) – Overwhelming stocks appeared first on Stocks Equity .
BioCryst Presents New Long-term and Real-world Data Demonstrating Sustained Reductions in Hereditary Angioedema Attack Rates and Improvement in Quality of Life with ORLADEYO (berotralstat) 2023/02/24 12:00:00 Wallstreet:Online
— Final safety and effectiveness analysis from APeX-S showed ORLADEYO 150 mg resulted in a median attack rate of 0.0 attacks per month in 20 of 24 months — RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new data from the APeX-S and APeX-2 clinical trials which evaluated oral, once-daily ORLADEYO (berotralstat)
Watch this stock’s price performance: BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) 2022/11/30 18:24:00 US Post News
In the current trading session, BioCryst Pharmaceuticals Inc.’s (BCRX) stock is trading at the price of $12.96, a gain of 2.53% over last night’s close. So, the stock is trading at a price that is -35.17% less than its 52-week high of $19.99 and 70.30% better than its 52-week low of $7.61. Based on the […]
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Israeli Ministry of Health 2022/11/28 12:00:00 GlobeNewswire
RESEARCH TRIANGLE PARK, N.C., Nov. 28, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Israeli Ministry of Health has granted marketing authorization for oral, once-daily ORLADEYO ® (berotralstat) to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older in Israel.
BioCryst Announces Approval of ORLADEYO (berotralstat) by the Israeli Ministry of Health 2022/11/28 12:00:00 Wallstreet:Online
RESEARCH TRIANGLE PARK, N.C., Nov. 28, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Israeli Ministry of Health has granted marketing authorization for oral, once-daily ORLADEYO (berotralstat) to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older in Israel. “We continue to make significant
Will BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) Stock Boom Or Bust From Here? 2022/11/18 19:00:00 Marketing Sentinel
During the recent session, BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)’s traded shares were 0.43 million, with the beta value of the company hitting 1.98. At the last check today, the stock’s price was $12.37, reflecting an intraday gain of 1.23% or $0.15. The 52-week high for the BCRX share is $19.99, that puts it down -61.6 from … Will BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) Stock Boom Or Bust From Here? Read More »
BioCryst Pharmaceuticals Inc.’s (NASDAQ: BCRX) Stock Price Will Be Bearish Or Bullish In 2022 2022/11/17 16:00:00 Stocks Register
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) shares, rose in value on Wednesday, 11/16/22, with the stock price down by -2.64% to the previous day’s close as strong demand from buyers drove the stock to $12.89. Actively observing the price movement in the last trading, the stock closed the session at $13.24, falling within a range of $12.85 … BioCryst Pharmaceuticals Inc.’s (NASDAQ: BCRX) Stock Price Will Be Bearish Or Bullish In 2022 Read More »
Why BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) Stock Should Not Be Discarded By Investors In 2022 2022/06/01 16:00:00 Marketing Sentinel
In today’s recent session, 0.47 million shares of the BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) have been traded, and its beta is 2.50. Most recently the company’s share price was $9.42, and it changed around $0.11 or 1.18% from the last close, which brings the market valuation of the company to $1.60B. BCRX at last check was … Why BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) Stock Should Not Be Discarded By Investors In 2022 Read More »
If You Don’t Bullish On BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) Now, You’ll Regret Your Decision Later 2022/05/31 16:00:00 Stocks Register
The trading price of BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) floating lower at last check on Tuesday, May 31, trading at $9.55, -2.15% lower than its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << Traders who pay close attention to intraday price movement should know that it … If You Don’t Bullish On BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) Now, You’ll Regret Your Decision Later Read More »
INTERNATIONAL BIOTECHNOLOGY TRUST PLC Buys 2, Sells 3 in 1st Quarter 2022/05/20 19:00:07 GuruFocus
Related Stocks: BCRX , NVAX , AMGN , ALNY , GILD ,
2022 Life Sciences Awards: BioCryst Pharmaceuticals Inc. 2022/05/20 02:29:23 Business Journals
Meet the winners in our 2022 Life Sciences Awards!
7 Cheap Biotech Stocks to Buy Now 2022/05/19 22:00:38 InvestorPlace
This article covers seven cheap biotech stocks for investors with a high risk tolerance. ImmunityBio ( IBRX ): Boasts an extensive pipeline that covers multiple chronic conditions. Selecta Biosciences ( SELB ): Clinical-stage biotech with truckloads of cash to take its novel immune tolerance platform past the finish line. Bluebird Bio ( BLUE ): Speculative biotech with a colossal growth runway if the FDA gives its gene therapies the green light. Vistagen Therapeutics ( VTGN ): Unique portfolio of therapeutics which target the nervous system in an industry set for tremendous growth ahead. BioNano Genomics Inc ( BNGO ): This meme stock could develop a long-term recurring revenue-generating machine with its genome image editing tool. Verastem ( VSTM ): This startup develops novel cancer treatments with the goal of delivering the best-in-class RAS pathway product. BioCryst Pharmaceuticals ( BCRX ): Biotech with a robust rare disease drug portfolio and strong liquidity. Source: Mongkolchon Akesin / Shutterstock.com Amidst immense market volatility, investors favor value-oriented sectors to minimize risk.
関連キーワード （バイオテクノロジ―_メディカルリサ―チ 米国株 バイオクリスト・ファ―マシュ―ティカルズ BCRX BioCryst Pharmaceuticals Inc.）